Company intelligence / Profile preview

Oleaphen

Monroe, Louisiana, United States

Ownership: Private
Development stage: Other

Overview

Oleaphen is a biotechnology company focused on developing novel therapeutic and nutraceutical interventions derived from olive-based polyphenols. The company specifically targets neurodegenerative conditions, such as Alzheimer's disease, by leveraging the neuroprotective properties of oleocanthal and other phenolic compounds. Their research emphasizes the ability of these compounds to reduce amyloid-beta aggregation and tau phosphorylation, which are key hallmarks of cognitive decline. Oleaphen aims to bridge the gap between clinical nutrition and pharmaceutical intervention to provide accessible brain health solutions.

Therapeutic areas: Neurology
Modalities: Small moleculeNatural product extract
Industry: Biotech

Beyond the preview

Go deeper on Oleaphen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oleaphen.

Explore the full profile